Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 628Neoplasm Metastasis 38HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Inflammatory Breast Neoplasms 20Brain Neoplasms 18Stomach Neoplasms 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Triple Negative Breast Neoplasms 12Colorectal Neoplasms 10Pancreatic Neoplasms 9Endometrial Neoplasms 9Ovarian Neoplasms 8Cardiotoxicity 8Lung Neoplasms 7Esophageal Neoplasms 7Breast Diseases 7Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pathologic Complete Response 5Carcinoma, Ductal, Breast 5Urinary Bladder Neoplasms 4Sarcoma 4HER2-positive Early Breast Cancer 4HER2 Positive Breast Cancer 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3

Interventions

Fulvestrant 6Letrozole 4Capecitabine 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × Trastuzumab × Breast × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

NCT05301010 2023-02-27

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Metastatic

NCT05301530 2022-03-29

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 1 Completed
50 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡